Related Experiment Videos
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.
1Research Group Pharmacological Haemostaseology, Medical Faculty, Friedrich Schiller University Jena, Jena, Germany. goetz.nowak@med.uni-jena.de
Pathophysiology of Haemostasis and Thrombosis
|December 8, 2004
Summary
The ecarin clotting time (ECT) accurately measures direct thrombin inhibitors, proving valuable in research and clinical settings, especially for monitoring argatroban therapy. Various ECT modifications enhance its utility across diverse applications.
Area of Science:
- Biochemistry
- Pharmacology
- Clinical Diagnostics
Background:
- The ecarin clotting time (ECT) is a crucial meizothrombin generation assay.
- It precisely quantifies direct thrombin inhibitors.
- ECT has a decade-long track record in research and clinical practice.
Purpose of the Study:
- To review the biochemical principles and measurement techniques of the ECT.
- To survey various ECT modifications for preclinical and clinical applications.
- To discuss the advantages and disadvantages of different ECT methods.
Main Methods:
- Review of existing literature on ECT.
- Description of biochemical background and measuring principle.
- Survey of modified ECT assays for diverse settings.
Main Results:
- ECT is highly effective for drug monitoring, particularly in argatroban therapy.
- Numerous modifications have adapted ECT for clinical requirements.
- ECT is applicable in biochemical investigations, point-of-care testing, and cardiac surgery.
Conclusions:
- The ECT is a versatile and valuable tool for quantifying direct thrombin inhibitors.
- Modified ECT methods offer flexibility for various diagnostic and monitoring needs.
- ECT demonstrates significant utility in both research and routine clinical practice.